SkinJect

Pittsburgh, United States Founded: 2015 • Age: 11 yrs
Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed.

About SkinJect

SkinJect is a Healthcare company based in Pittsburgh (United States) founded in 2015. Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed. It operates on a HealthTech model. SkinJect has raised $3.4 million across 4 funding rounds from investors including Velocity Fund Partners. Its chief executive, as recorded, is James M Nolan. SkinJect offers products and services including SkinJect Patch. Its focus areas include Medical Devices and Dermatological Devices. Its competitors include Enable Injections, Aura Biosciences and Micron Biomedical; 3 of its 3 listed competitors have raised funding.

Company details

SkinJect is engaged in the development of innovative solutions for treating basal cell and squamous cell skin cancer. A dissolvable microneedle patch is being created as a less invasive and less painful treatment option. The company operates in the dermatology sector, addressing an unmet clinical need with a focus on reducing recurrence rates. Efforts are directed toward advancing technologies and securing regulatory clearances for commercialization in a competitive market.

  • Headquarters Pittsburgh, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website skinjectpatch.com
  • Social LinkedIn X
Key Metrics
  • Total Equity Funding
    $3.4M (USD)

    in 4 rounds

  • Latest Funding Round
    $895.09K (USD), Series A

    Jul 2021

  • Investors

Products & Services of SkinJect

SkinJect offers a comprehensive portfolio of products and services, including SkinJect Patch.

SkinJect Patch
Medical Device

A microneedle patch developed for skin cancer treatment.

Funding Insights of SkinJect

SkinJect has successfully raised a total of $3.4M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $895.09 thousand completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $3.4M
  • Total Rounds 4
  • Last Round Series A β€” $895,091
  • First Round $500,000

    (Dec 2015)

  • Investors Count 1

All 4 funding rounds of SkinJect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2021$895,091Series A––
–
May 2019$2.5MSeries A––
–
May 2016Seed––
Dec 2015$500,000Debt – Conventional––
–
Valuation history

1 investors in total: 1 institutional.

Investors in SkinJect

SkinJect has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Velocity Fund Partners.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Private equity investments are directed toward USA-based companies.
2016velocityfp.comPittsburgh, United States
Premium access

Investor details for SkinJect

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of SkinJect

4 people are tracked at SkinJect (4 in leadership).

NameRoleGroup
James M Nolan
CEOLeadership
Michael J. Fare
President & COOLeadership
Joseph Donnelly
CFOLeadership
O. Burak Ozdoganlar
Chief Technical AdvisorLeadership
Premium access

Complete people profiles for SkinJect

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of SkinJect

3 dated milestones of SkinJect across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded SkinJect is founded.
  2. Funding First funding round of $500K.
  3. Funding Latest funding round, Series A, of $895K.

Competitors of SkinJect

SkinJect has 3 listed competitors in our database, 3 of them funded. They include Enable Injections, Aura Biosciences and Micron Biomedical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
enableinjections.com2010Cincinnati, United States$304.27M185
Provider of a wearable drug delivery solution
aurabiosciences.com2007Cambridge, United States$215.46M21
Therapies are developed to target and destroy cancer cells selectively.
micronbiomedical.com2014Atlanta, United States$33M11
Microneedle patches are developed for vaccine and drug delivery.
Premium access

Detailed competitors of SkinJect

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as SkinJect (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Skinject

Premium access

Complete news archive for SkinJect

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SkinJect

SkinJect was founded in 2015.

SkinJect is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.

James M Nolan is the CEO of SkinJect, as recorded in our data.

SkinJect is a funded company, having raised a total of $3.4M across 4 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $500K, raised on Dec 2015.

SkinJect is engaged in the development of innovative solutions for treating basal cell and squamous cell skin cancer. A dissolvable microneedle patch is being created as a less invasive and less painful treatment option. The company operates in the dermatology sector, addressing an unmet clinical need with a focus on reducing recurrence rates. Efforts are directed toward advancing technologies and securing regulatory clearances for commercialization in a competitive market.

SkinJect's top competitors include Enable Injections, Aura Biosciences and Micron Biomedical.

SkinJect offers SkinJect Patch.

SkinJect has 1 investor. Key investors include Velocity Fund Partners.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available